Study of MCF chemotherapy for unknown primary cancer
Author Information
Author(s): Macdonald A G, Nicolson M C, Samuel L M, Hutcheon A W, Ahmed F Y
Primary Institution: Aberdeen Royal Infirmary
Hypothesis
Can the combination of mitomycin C, cisplatin, and continuous infusion 5-fluorouracil improve outcomes in patients with carcinoma of unknown primary site?
Conclusion
The MCF regimen is tolerable and shows comparable response rates and survival data to other chemotherapy regimens for carcinoma of unknown primary site.
Supporting Evidence
- The overall response rate was 27%, with 3% complete responses and 23% partial responses.
- Median time to progression was 3.4 months and median overall survival was 7.7 months.
- 28% of patients survived for 1 year and 10% for 2 years.
Takeaway
Doctors tested a new combination of medicines to help patients with cancer that doesn't have a known starting point, and it worked for some of them.
Methodology
Patients with carcinoma of unknown primary were treated with MCF chemotherapy every 21 days for up to six cycles, and their responses were evaluated.
Potential Biases
Potential selection bias due to the single-center design.
Limitations
The study had a small sample size and lacked a control group.
Participant Demographics
Patients aged 18 to 75 with a confirmed diagnosis of carcinoma of unknown primary.
Statistical Information
P-Value
p<0.0001 for improved survival with chemotherapy in a related study.
Confidence Interval
95% CI 1.1–5.6 months for time to progression; 95% CI 5.7–9.8 months for overall survival.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website